AMEXHealth CareBiotechnologySnapshot 2026-07-23
Reading CLDI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it is attempting to advance its drug development while navigating a challenging financial landscape.
The market seems to have priced in significant uncertainty due to the company's ongoing losses and high risk. There is also a potential expectation that the healthcare sector's positive momentum could provide some support.
Management is focused on filing an IND for CLD-401 by the end of 2026, which is on track. However, the company continues to face challenges in controlling operating losses and cash burn, with a mixed trajectory in recent performance.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could provide a favorable backdrop for CLDI. Conversely, any guidance cuts or poor performance from these peers could negatively impact CLDI.
Over the next 1 to 3 years, CLDI's outlook remains uncertain, driven by high risk and ongoing losses, but it could benefit from favorable sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Less loss means better financial health. This can help investors feel more confident.
Confirms:Operating losses decrease year over year in Q2 2026.
Disproves:Operating losses increase or stay the same in Q2 2026.
Why it matters: Filing the IND is a key step for Calidi's lead drug. It shows progress in getting CLD-401 into clinical trials.
Confirms:The IND for CLD-401 is filed by December 31, 2026.
Disproves:The IND filing is delayed beyond 2026 without a clear reason.
Why it matters: Reducing cash burn is vital for financial health. It shows better cost management.
Confirms:Cash burn rate decreases compared to Q1 2026.
Disproves:Cash burn rate increases compared to Q1 2026.
Why it matters: New data can increase trust in CLD-401's potential. This may draw in investors.
Confirms:Positive data presented at a major conference, like ASGCT or AACR.
Disproves:There is negative or unclear data shown at these conferences.
